BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12641328)

  • 1. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.
    Swanepoel E; Liebenberg W; Devarakonda B; de Villiers MM
    Pharmazie; 2003 Feb; 58(2):117-21. PubMed ID: 12641328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa.
    Liebenberg W; Dekker TG; Lötter AP; de Villiers MM
    Drug Dev Ind Pharm; 1998 May; 24(5):485-8. PubMed ID: 9876612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs.
    Swanepoel E; Liebenberg W; de Villiers MM
    Eur J Pharm Biopharm; 2003 May; 55(3):345-9. PubMed ID: 12754010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole.
    de Villiers MM; Terblanche RJ; Liebenberg W; Swanepoel E; Dekker TG; Song M
    J Pharm Biomed Anal; 2005 Jul; 38(3):435-41. PubMed ID: 15925244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysing the crystal purity of mebendazole raw material and its stability in a suspension formulation.
    Agatonovic-Kustrin S; Glass BD; Mangan M; Smithson J
    Int J Pharm; 2008 Sep; 361(1-2):245-50. PubMed ID: 18555626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A discriminating dissolution method for glimepiride polymorphs.
    Bonfilio R; Pires SA; Ferreira LM; de Almeida AE; Doriguetto AC; de Araújo MB; Salgado HR
    J Pharm Sci; 2012 Feb; 101(2):794-804. PubMed ID: 22052673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms.
    Paaver U; Lust A; Mirza S; Rantanen J; Veski P; Heinämäki J; Kogermann K
    Int J Pharm; 2012 Jul; 431(1-2):111-9. PubMed ID: 22554403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of solid-state forms of mebendazole.
    Kumar S; Chawla G; Sobhia ME; Bansal AK
    Pharmazie; 2008 Feb; 63(2):136-43. PubMed ID: 18380400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution and spectrophotometric determination of astaxanthin in aqueous solutions.
    Tichý E; Zabka M; Gardavská K; Halenárová A; Scheerová ZK; Potúcková M
    Pharmazie; 2011 Aug; 66(8):560-3. PubMed ID: 21901976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs.
    Park SH; Choi HK
    Int J Pharm; 2006 Sep; 321(1-2):35-41. PubMed ID: 16797892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A; Cavallari C; Ospitali F
    Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution test for ivermectin in oral veterinary paste.
    Sznitowska M; Pietkiewicz J; Stokrocka M; Janicki S
    Pharmazie; 2004 Oct; 59(10):814-5. PubMed ID: 15544065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dissolution and physical stability of micronized nifedipine particles encapsulated with a biocompatible polymer and surfactants in a wet ball milling process.
    Li N; DeGennaro MD; Liebenberg W; Tiedt LR; Zahr AS; Pishko MV; de Villiers MM
    Pharmazie; 2006 Jul; 61(7):595-603. PubMed ID: 16889066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a universal dissolution medium for carbamazepine.
    El-Massik MA; Abdallah OY; Galal S; Daabis NA
    Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties.
    Zimmermann A; Millqvist-Fureby A; Elema MR; Hansen T; Müllertz A; Hovgaard L
    Eur J Pharm Biopharm; 2009 Jan; 71(1):109-16. PubMed ID: 18619536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole.
    Brits M; Liebenberg W; de Villiers MM
    J Pharm Sci; 2010 Mar; 99(3):1138-51. PubMed ID: 19691117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C.
    Martins FT; Neves PP; Ellena J; Camí GE; Brusau EV; Narda GE
    J Pharm Sci; 2009 Jul; 98(7):2336-44. PubMed ID: 18855910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
    Overhoff KA; Engstrom JD; Chen B; Scherzer BD; Milner TE; Johnston KP; Williams RO
    Eur J Pharm Biopharm; 2007 Jan; 65(1):57-67. PubMed ID: 16987642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant.
    Sheng JJ; Kasim NA; Chandrasekharan R; Amidon GL
    Eur J Pharm Sci; 2006 Nov; 29(3-4):306-14. PubMed ID: 16982177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.